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Abstract: Conventional methods for radiolabelling proteins are time consuming and difficult to automate.
In this article, Jason P. Holland discusses how combining photochemistry with radiochemistry enables
development of radiolabelled proteins far more quickly and easily – literally in a flash of light.
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Radiopharmaceuticals are a cornerstone of modern Nuclear Medicine but the constraints of 
working with radioactivity mean that these advanced technologies are often limited places that 
have the capability of producing radioactive drugs in-house. The exquisite affinity, selectivity and 
pharmacokinetic properties of monoclonal antibodies (mAbs) and related biologically active 
fragments or biosimilars make them attractive starting points for developing targeting agents for 
immuno-positron emission tomography (immuno-PET) and radioimmunotherapy (RIT). 
However, for many small-to-medium sized medical centres, options for radiopharmaceutical 
production are limited due to the complexity of production and associated high costs. Alternative 
chemical routes that simplify the production of radiolabelled antibodies are the key to improving 
access.  
 
CHEMISTRY lies at the core of drug discovery and radiotracer development. When it comes to 
working with radioactivity, time is one of the most crucial parameters.(1) The chemical reactions 
used to incorporate a radioactive atom into a small-drug molecule or an antibody must be fast, 
efficient, high-yielding and reliable. For production of radiolabelled antibodies (and other proteins) 
using nuclides such as 64Cu, 68Ga, 90Y or 89Zr etc, the process typically involves two distinct steps 
(Figure 1). First, the protein is pre-purified from a stabilised formulated source, followed by 
functionalisation to add a chelate that binds radioactive metal ions, and then the intermediate 
construct (the functionalised-mAb) is re-purified. Prior to translation, the chemical, physical and 
biological properties of the intermediate must be characterised, and then the material must be 




Classical manual batch processes dominate the production of radiolabelled antibodies for 
preclinical and clinical applications but recent advanced from the team in Amsterdam have also 
shown that the radiolabelling step and purification can be automated.(2) With current clinical 
solutions, one of the main impediments to the more widespread use of radiolabelled antibodies is 
the requirement to functionalise, isolate, characterise and store the intermediate protein. In 
accordance with the regulations from most major authorities, including the United States Federal 
Drug Administration, the European Medicines Agency and Swiss Medic, the functionalised 
intermediate is often classified as a new molecular entity (NME), and therefore, is subject to 
stringent adsorption, distribution, metabolism, excretion and toxicological (ADME-tox) testing 
before it can be used in human trials. Providing full ADME-tox data is time consuming, expensive 
and is often beyond the reach of most research groups or small medical facilities. Furthermore, 
limits on the physical quantities of conjugated antibodies that can be produced in the two-step 
process also present challenges to fulfilling the regulatory requirements.  
 
From thermochemistry to photochemistry 
A potential solution to the financial, legislative and practical problems of making 
radiolabelled antibodies is to seek alternative technologies. Traditional methods for adding the 
chelate to the antibody use chemical reactions that are stimulated by heat. Many different options 
exist but in general, the most widely used conjugation reactions are dominated by modification of 
the mAb at either cysteine (thiolate) resides using maleimido-based reagents, or lysine residues 
using chelates bearing N-hydroxysuccinimide (NHS) or isothiocyanate (NCS) groups.(3,4) The 




radiolabelling step, and the reaction conditions are not suited for developing simplified one-pot 
procedures.  
 Switching from classical thermochemically mediated reactions to photochemically-
induced conjugation has the potential to solve some of the aforementioned issues associated with 
making radiolabelled antibodies.(5–7) The hypothesis was simple – by using different reactive 
units that become activated under irradiation with mild ultraviolet (UVC) light, and are compatible 
with standard formulation buffers and labelling conditions, it may be possible to combine the 
bioconjugation and radiolabelling steps into a simultaneous, one-pot procedure. The world of 
photochemistry provided several viable options for selecting reactive groups may potentially be 
combined with Good Manufacturing Process (GMP)-grade antibodies. These include many 
photoactive reagents based on benzophenones, diazirenes and aryl azides that were originally 
popularised as tools for photoaffinity labelling.(8,9) To narrow the choice, parallel requirements 
were that the photoactive groups should also generate highly reactive intermediates that are stable 
to the background media (specifically, water, oxygen and various salts at high ionic strength), and 
undergo fast, chemoselective bimolecular reactions with proteins. Furthermore, the irradiation 
conditions should not induce damage to the underlying structure of the protein.  
  
Photoradiosynthesis with aryl azides 
 While many photoactive groups exist, the constraints of working in biologically compatible 
aerated media with high salt content, a narrow acidity window (ca. pH 5 – 9), and the need to 
perform biomolecular reactions without pre-association of the chelate to the antibody limits the 
choice. Photoaffinity labelling has been successful with reagents that generate carbenes, nitrenes 




radicals makes it very difficult to control the conditions so that productive biomolecular coupling 
to the antibody occurs at a rate that exceeds background quenching reactions with the solvent, 
dioxygen, or other species in the mixture. In contrast, aryl azides (and more generally aromatic 
azide species) also produce several short-lived, highly reactive intermediates, the parent of which 
is the photolytically produced by loss of N2(g) as open-shell singlet nitrene (PhN1) that has a half-
life on the order of a nanosecond.(11) Intramolecularly rearrangement is the kinetically favoured 
pathway for the PhN1 and rearrangement first produces a bicyclic benzazirene which undergoes 
ring insertion of the nitrogen atom and expansion to form a 7-membered ketenimine ring. Density 
functional theory calculations have shown that this ketenimine reacts chemo-selectively with 
primary amines such as the e-NH2 side-chain of a lysine residue which are present in abundance 
on the solvent exposed surface of in antibodies. The reaction is photoinitiated at 365 nm but the 
bimolecular coupling step remains under thermal control. Calculations (B3LYP/6-
311++G(d,p)/PCM) of the reaction pathway confirmed that overall the coupling reaction is 
thermodynamically feasible (DrG = –166 kJ mol-1) with a low thermodynamic barrier to 
nucleophilic attack of a primary amine on the ketenimine ring (DTSG = +54 kJ mol-1). Much like, 
‘The Story of the Three Bears’ by Robert Southey, it is perhaps fortuitous that photoinitiated 
activation of aryl azides generates reactive intermediates that not too reactive but operate in just 
the right kinetic window to facilitate rapid photochemical conjugation whilst mostly avoiding 
competitive non-productive quenching reactions.  
 Immuno-PET studies with varies radiotracers including 89ZrDFO-azepin-trastuzumab for 
molecular imaging of HER2/neu receptors in ovarian, breast, gastrointestinal and other cancers 
confirmed that photoradiosynthesis can produce viable imaging agents (Figure 3). Additional 




photodegraded by irradiation with light at 365 or 395 nm, which makes aryl azides versatile 
reagents for future developments of photochemically mediated protein ligation reactions.  
 
The future is bright 
Radiopharmaceuticals represent just one potential area whereby photochemistry may have an 
impact in clinic drug development. Of the top ‘10 block buster’ in 2018, 7 were classified as 
biologics with most based on monoclonal antibodies. Antibodies are certainly important, but 
experience has found that as a monotherapy, antibodies are limited by poor tissue penetration and 
other morphological, genetic and pharmacological factors that limit their therapeutic index. To 
circumvent some of these issues and to improve potency, pharmaceutical companies and research 
groups alike are turning their attention toward antibody-drug conjugates (ADCs). There are now 
4 US-FDA approved ADCs and the development of extremely expensive drugs like brentuximab 
vedotin (AdcetrisTM) or trastuzumab emtansine (Kadcyla™) requires the development of efficient, 
reliable and sophisticated conjugation chemistries that provide not only chemoselective 
functionalisation but also regioselective, stereoselective and stoichiometrically precise products. 
Photochemistry may not be able to solve all of the challenges, but as early experiments using 
radioactivity have shown, in the future, the synthesis of complex drugs might be as simple as 
switching on the light! 
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Figure 1. Established two-step (top) and recent one-step simultaneous (bottom) strategies used to 
functionalise and radiolabel antibodies and other proteins for immuno-PET. 
 
 











Figure 3. Small-animal immuno-PET images of 89ZrDFO-azepin-trastuzumab in mice bearing 
subcutaneous SK-OV-3 human ovarian tumours. H = leart, L = liver, Sp = spleen, T = tumour. 
 
